Profile data is unavailable for this security.
About the company
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
- Revenue in USD (TTM)8.00k
- Net income in USD-25.78m
- Incorporated2001
- Employees23.00
- LocationGenelux Corp2625 Townsgate Road, Suite 230WESTLAKE VILLAGE 91361United StatesUSA
- Phone+1 (805) 267-9889
- Fax+1 (302) 636-5454
- Websitehttps://genelux.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FitLife Brands Inc | 58.51m | 7.30m | 127.83m | 37.00 | 18.93 | 4.38 | 17.37 | 2.20 | 1.48 | 1.48 | 11.87 | 6.39 | 1.20 | 3.87 | 27.13 | 1,581,351.00 | 15.03 | 26.40 | 19.37 | 33.92 | 41.55 | 42.09 | 12.48 | 17.65 | 0.5177 | 12.32 | 0.3582 | -- | 82.97 | 25.28 | 19.58 | 67.31 | -- | -- |
| PDS Biotechnology Corp | 0.00 | -43.89m | 130.58m | 25.00 | -- | 3.33 | -- | -- | -1.37 | -1.37 | 0.00 | 1.01 | 0.00 | -- | -- | 0.00 | -63.85 | -51.63 | -74.22 | -59.00 | -- | -- | -- | -- | -- | -27.82 | 0.3933 | -- | -- | -- | -5.11 | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -82.78m | 131.55m | 65.00 | -- | 1.33 | -- | -- | -2.12 | -2.12 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -52.16 | -- | -54.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Karyopharm Therapeutics Inc | 140.46m | -146.34m | 131.84m | 325.00 | -- | -- | -- | 0.9302 | -1.28 | -1.28 | 1.22 | -1.45 | 0.5298 | 1.67 | 4.24 | 432,187.70 | -55.19 | -53.02 | -72.56 | -65.85 | 96.08 | 97.18 | -104.18 | -125.15 | 2.99 | -9.66 | 2.25 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -37.35m | 131.89m | 22.00 | -- | 1.49 | -- | -- | -0.2367 | -0.2367 | 0.00 | 0.4989 | 0.00 | -- | -- | 0.00 | -37.14 | -30.26 | -39.48 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Adicet Bio Inc | 0.00 | -139.79m | 132.30m | 143.00 | -- | 0.5175 | -- | -- | -2.95 | -2.95 | 0.00 | 3.15 | 0.00 | -- | -- | 0.00 | -46.75 | -37.03 | -49.70 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| aTyr Pharma Inc | 588.00k | -53.93m | 134.57m | 56.00 | -- | 1.51 | -- | 218.30 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Genelux Corp | 8.00k | -25.78m | 135.52m | 23.00 | -- | 8.56 | -- | 16,400.52 | -0.9811 | -0.9811 | 0.0003 | 0.5679 | 0.0004 | -- | -- | 347.83 | -131.24 | -- | -246.21 | -- | -- | -- | -322,287.50 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -24.86m | 136.36m | 28.00 | -- | 3.15 | -- | -- | -0.5113 | -0.5113 | 0.00 | 0.6804 | 0.00 | -- | -- | 0.00 | -50.58 | -38.31 | -59.70 | -43.34 | -- | -- | -- | -- | -- | -12.88 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| Seres Therapeutics Inc | 126.85m | -82.68m | 137.83m | 233.00 | -- | -- | -- | 1.12 | -0.6062 | -0.6062 | 0.9495 | -0.3945 | 0.4149 | -- | -- | 544,407.80 | -27.04 | -41.51 | -36.82 | -54.13 | -- | -- | -65.18 | -170.14 | 1.25 | -9.21 | 2.41 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| Scpharmaceuticals Inc | 17.63m | -57.71m | 137.91m | 135.00 | -- | 5.20 | -- | 7.24 | -1.49 | -1.49 | 0.4545 | 0.6814 | 0.1713 | 0.7566 | 4.02 | 130,607.40 | -56.07 | -38.23 | -62.13 | -42.31 | 71.69 | -- | -327.29 | -1,360.16 | 5.44 | -16.60 | 0.6159 | -- | -- | -- | -48.79 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | -67.33k | 141.57m | 17.00 | -- | -- | -- | -- | -0.0004 | -0.0004 | 0.00 | -0.0045 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.19 | 1.74 | -- | -- | -- | 99.69 | -- | -- | -- |
| Renovaro Inc | 0.00 | -53.93m | 141.60m | 11.00 | -- | 0.8223 | -- | -- | -0.7661 | -0.7661 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -37.06 | -27.81 | -41.75 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| I-Mab ADR | 3.82m | -202.42m | 142.35m | 220.00 | -- | 0.5986 | -- | 37.29 | -2.43 | -2.43 | 0.0459 | 2.94 | 0.0083 | -- | -- | 17,353.44 | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -4.66 | -- |
Data as of May 22 2024. Currency figures normalised to Genelux Corp's reporting currency: US Dollar USD
18.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.13m | 4.22% |
| Woodward Diversified Capital LLCas of 31 Mar 2024 | 1.09m | 4.04% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.00m | 3.73% |
| Geode Capital Management LLCas of 31 Mar 2024 | 424.27k | 1.58% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 395.02k | 1.47% |
| Millennium Management LLCas of 31 Mar 2024 | 261.80k | 0.97% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 162.49k | 0.61% |
| Provident Wealth Management LLCas of 31 Mar 2024 | 157.14k | 0.59% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 152.51k | 0.57% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 100.40k | 0.37% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
